Tribulus: Saponins, Product Quality and Safety
Two bottles labelled "Tribulus terrestris extract, 750 mg, standardized to 45% saponins" can contain substantially different amounts of every compound anyone has ever proposed as the active one. That is not a cynical guess — it is what the analytical chemistry literature reports, and it is the most under-appreciated fact about this herb. It explains why trials disagree, why one person's experience does not predict another's, and why a study of a Bulgarian fruit extract tells you very little about a capsule of Indian aerial-part powder.
This page covers the chemistry behind that variability, how to read a label that is technically accurate and practically meaningless, and the safety file — which is not empty. There are published case reports of serious kidney injury and of liver injury associated with tribulus products, gynecomastia has been reported in men taking them, a priapism case has been published, and tribulus-branded products have caused positive doping tests through undeclared steroid contamination. There is also a well-documented veterinary syndrome, tribulosis, in livestock grazing the whole plant, which is distinct from human supplement use but is the clearest available proof that this plant is biologically active rather than inert.
Table of Contents
- The Saponins: Protodioscin and Its Relatives
- Why “45% Saponins” Means Almost Nothing
- Plant Part, Geography and Season
- The Bulgarian Sourcing Claim, Examined
- How Saponin Content Is Measured — and Mis-measured
- Reading a Real Label
- Doses Used in Trials
- Documented Harms: Liver and Kidney
- Gynecomastia and Priapism
- Adulteration and Doping Positives
- Ruminant Tribulosis: The Veterinary Context
- Interactions and Who the Research Raises Concerns For
- What the Research Says About Product Quality
- Key Research Papers
- Connections
- Featured Videos
The Saponins: Protodioscin and Its Relatives
Saponins are plant compounds built from a steroid or triterpene core with one or more sugar chains attached. The name comes from their soap-like behaviour — shake a saponin solution and it foams, because the molecule has a fat-soluble end and a water-soluble end. In plants they generally serve defensive roles, deterring grazing and inhibiting microbes and fungi. That defensive origin is a useful thing to keep in mind: saponins are not neutral nutrients, and their biological activity is the point of them.
Tribulus contains a large family of steroidal saponins, divided into two structural classes that matter more than the terminology suggests:
- Furostanol saponins — including protodioscin, the molecule almost always named as the presumed active constituent and the one most products claim to standardize to. Furostanols carry an additional sugar at a position that makes them relatively unstable: heat, acid and enzymes can convert a furostanol into the corresponding spirostanol. This means processing history changes the chemistry, not just the yield.
- Spirostanol saponins — including dioscin, the conversion product of protodioscin, plus tribulosin, terrestrosins and others. These are more stable, and a poorly handled or aggressively processed extract will be richer in spirostanols and poorer in the furostanol it was sold on.
Beyond the saponins, tribulus contains flavonoids (including rutin and quercetin derivatives), small quantities of beta-carboline alkaloids (harman and harmine, which are centrally active compounds in other contexts and whose relevance at extract doses is unresolved), phytosterols, tannins and various minor constituents. Reviews such as Saponins in Tribulus terrestris — chemistry and bioactivity (Phytochemistry Reviews, 2005) and Phytopharmacological overview of Tribulus terrestris (Pharmacognosy Reviews, 2014) catalogue this chemistry in detail.
An important honesty point before going further: nobody has established which of these compounds, if any, is responsible for any human effect. Protodioscin is the industry's designated active ingredient largely by convention and by inheritance from the animal literature, not because a human trial isolated it and demonstrated an effect. Standardizing to protodioscin is therefore standardizing to a plausible marker — better than standardizing to nothing, but not the same as standardizing to a known active dose. Evidence tier for protodioscin as the active constituent: preliminary (animal and in-vitro), unconfirmed in humans.
Why “45% Saponins” Means Almost Nothing
The number on the front of the bottle is the industry's proxy for potency. Here is why it does not do the job it appears to do. When the first chromatographic method for tribulus saponins was applied to market products in 2001, their protodioscin content ranged from 0.17% to 6.49%.
- "Total saponins" is a category, not a compound. A 45% total-saponin extract could be dominated by protodioscin, or by spirostanols with different activity, or by minor saponins nobody has studied. Two extracts with identical total-saponin figures can have completely different composition. The number tells you a class abundance, and the class is chemically and biologically heterogeneous.
- The measured value depends on the assay. Different quantification methods — gravimetric approaches, spectrophotometric assays against a reference standard, and chromatographic methods — return different numbers for the same material, sometimes very different. There is no single universally applied compendial method that all suppliers use, so "45%" is a number produced by a method that is usually not disclosed.
- The reference standard matters. A spectrophotometric assay reports saponin content relative to a chosen standard compound. Change the standard and the percentage changes without the material changing at all.
- Percentage is of extract, and extract ratios vary. "45% saponins" applies to the extract powder. How much raw plant went into that powder, and by what solvent, differs between suppliers. Two products can both be "45%" while representing quite different plant inputs.
- Nobody has established a target. Even if the figure were perfectly measured, there is no human dose-response curve linking saponin intake to any outcome. There is no evidence that 45% outperforms 20%, because the trial establishing that has not been run. Higher percentages are sold as better on the strength of the intuition alone.
- Front-label claims are not verified before sale. In the United States, dietary supplement labels are not pre-approved for accuracy; enforcement is after the fact. Independent testing programmes exist precisely because label figures cannot be assumed.
The practical upshot: the saponin percentage is best read as a rough signal that the manufacturer performs some quality control, and not as a potency specification you can compare across brands.
Plant Part, Geography and Season
The variability is not merely an analytical artefact. The underlying plant material genuinely differs, and this has been measured.
Determination of steroidal saponins in Tribulus terrestris by reversed-phase high-performance liquid chromatography and evaporative light scattering detection (Journal of Pharmaceutical Sciences, 2001) established a chromatographic method and applied it to tribulus material, documenting substantial differences in saponin content between samples. Distribution of steroidal saponins in Tribulus terrestris from different geographical regions (Phytochemistry, 2008) addressed the sourcing question directly, examining material from multiple regions and finding that saponin profiles differ by geographic origin — not only in total amount but in which saponins predominate. Samples from Bulgaria, Greece, Serbia, Macedonia, Turkey, Georgia and Iran shared one chemical profile, with protodioscin and prototribestin as the main components; samples from Vietnam and India had a totally different profile, lacking prototribestin and tribestin and carrying high amounts of tribulosin, which the authors take to be a different chemotype. The study did not include material from China, Africa, the Americas or Australia.
The factors that drive this:
- Plant part. Fruit, aerial parts (leaf and stem) and root differ in saponin content and profile. This is the single largest source of variation and it is often not stated on the label at all. A product that says only "Tribulus terrestris extract" has not told you which part of the plant you are buying — and the traditions differ too: Ayurvedic gokshura and Chinese bai ji li both centre on the fruit, while several commercial extracts are made from aerial parts.
- Geographic origin. Material from the Balkans, from India, from China, from Africa and from the plant's invasive range in the Americas and Australia differ in profile. Some regional chemotypes are notably poorer in the marker compound the market prizes.
- Season and growth stage. Saponin content shifts across the growing season and with the plant's reproductive stage. Harvest timing therefore changes the product.
- Growing conditions. Soil, water availability and stress exposure all affect secondary-metabolite production. Saponins are defence compounds; a stressed plant may make more of them.
- Extraction and processing. Solvent, temperature, pH and drying determine both how much is extracted and — because furostanols convert to spirostanols under heat and acid — what it turns into on the way.
The consequence for interpreting the literature is important and it is the reason this page sits alongside the others: the clinical trials on tribulus did not all test the same substance. When the libido page observes that two randomized trials in men reached opposite conclusions, extract identity is a live candidate explanation. And it cuts both ways — a positive trial's extract is not necessarily what is in the bottle you buy either.
The Bulgarian Sourcing Claim, Examined
"Bulgarian tribulus" is a marketing fixture, presented as a mark of superior potency. It deserves a plain look, because there is a kernel of substance wrapped in a great deal of packaging.
The kernel: Bulgaria is where the modern hormonal framing of tribulus originated, via a standardized preparation marketed from the 1980s. Bulgarian research institutions did work on the plant, Bulgarian material was the basis for the extract that generated the reputation, and a genuine domestic industry grew around it. If a specific trial used a specific Bulgarian extract, then that extract is the one with data attached to it — a real and legitimate point.
The packaging:
- "Bulgarian" is not a specification. It names a country, not a plant part, an extraction method, a saponin profile or a protodioscin figure. Bulgarian-grown aerial parts extracted carelessly are not superior to Indian fruit extracted well.
- Origin claims are hard to verify and easy to make. Nothing on a retail label proves geographic provenance, and no consumer-accessible test distinguishes Bulgarian material from other material.
- The regional-superiority claim is an empirical question with no clean answer. The chemistry literature shows that profiles differ by region; it does not establish that one region's material is clinically superior, because that would require head-to-head human trials, which do not exist. Evidence tier: not established.
- Origin cannot rescue a claim that failed in trials. The negative testosterone results were not attributable to poor sourcing — standardized extracts were used, including in the studies that generated the reputation's home region. Sourcing does not convert a NOT SUPPORTED claim into a supported one.
- The association with the original preparation is genealogical, not evidential. A modern product invoking a decades-old brand's country of origin has not thereby inherited its data.
So: Bulgarian origin is a reasonable thing for a manufacturer to state and a poor reason to pay a premium. What actually distinguishes products is disclosed plant part, a stated marker-compound figure with the method behind it, and independent batch testing.
How Saponin Content Is Measured — and Mis-measured
Knowing roughly how these numbers are produced makes it much easier to judge what a label is worth.
- Chromatographic methods (HPLC and related). Separate individual compounds and quantify them against authentic reference standards. This is the approach that can report an actual protodioscin figure, and it is what the analytical literature uses. Saponins are awkward analytes — many lack a strong ultraviolet-absorbing chromophore — so detection often requires evaporative light scattering, refractive index, or mass spectrometry rather than simple ultraviolet (UV) absorbance. This is the good method, and it is the expensive one.
- Spectrophotometric total-saponin assays. A colour-forming reaction followed by absorbance measurement, reported against a chosen standard. Cheap, fast, and prone to over-reporting because other plant constituents can react. Many "total saponins" percentages on the market come from methods of this family.
- Gravimetric methods. Weigh a crude fraction after selective precipitation or partitioning. Crudest of all, and it counts co-precipitating non-saponin material as saponin.
Consequences worth internalising:
- A stated protodioscin percentage is more informative than a total-saponin percentage, because it names a specific compound and generally implies a chromatographic method.
- A very high total-saponin claim is a reason for more suspicion, not less. Figures far above what the analytical literature reports for genuine extracts are more likely to reflect a permissive assay than exceptional material.
- Method disclosure is a quality signal. A manufacturer that states how it quantified its marker is telling you something real. Most do not.
- Batch-to-batch certificates of analysis are what actually matter, because the plant material changes between batches even for a conscientious supplier.
Reading a Real Label
What label features tell a reader, and which features the research links to problems.
Good signs:
- Plant part named — "fruit extract" or "aerial parts extract." Its absence means the most important variable is undisclosed.
- A specific marker compound with a percentage — protodioscin, ideally, rather than only total saponins.
- Extract ratio stated — how much raw herb the extract represents.
- Single ingredient. Only a single-ingredient product shows how much tribulus is actually present.
- Independent third-party testing, and for anyone drug-tested, batch certification specifically for banned substances.
- Batch number and expiry, with a certificate of analysis available on request.
Warning signs:
- "Proprietary blend." Legally permits a combined weight with no per-ingredient amounts. It exists so you cannot tell how little of the headline ingredient is present.
- A long ingredient list. Fourteen botanicals cannot each be present at a studied dose, and no trial has tested that combination.
- Explicit hormonal or anabolic claims — "anabolic," "steroidal support," "massive test increase." These are the products over-represented in contamination findings.
- Before-and-after physique photography, which is marketing, not data.
- Implausible saponin percentages with no method stated.
- No plant part, no marker compound, no batch number.
- Claims to raise testosterone. Aside from being NOT SUPPORTED (see the testosterone page), a brand willing to print a claim that controlled trials have refuted has told you how it treats evidence generally.
Doses Used in Trials
Presented as description, not recommendation — and read alongside the fact that no human dose-response relationship has been established for any outcome.
- Range in the literature: roughly 250 to 1,500 mg of extract per day, commonly divided across two or three doses and taken with food to reduce stomach upset.
- Sexual-function trials have clustered around 750 mg daily of a standardized extract.
- Durations in the trials run from a few weeks to about twelve weeks. Longer-term safety and efficacy are simply unstudied.
- Milligrams are not comparable across products. 750 mg of a well-characterised standardized extract and 750 mg of unstandardized powder are different quantities of whatever matters. The standardization, not the capsule weight, is what describes the amount.
- "Cycling" schedules are marketing conventions, not protocols derived from evidence. No trial has compared cycled with continuous use.
- More is not established as better. No human dose-response relationship has been established, while organ injury has been documented in case reports.
Documented Harms: Liver and Kidney
"Generally well tolerated" is the usual summary and it is broadly true for short-term use of a clean, standardized product — the common complaints are mild gastrointestinal upset, cramping and reflux, often improved by taking it with food. But "generally well tolerated" is not the whole record, and the rest of the record is what an honest page has to print.
Kidney injury
Tribulus terrestris-induced severe nephrotoxicity in a young healthy male was published in Nephrology Dialysis Transplantation in 2010. The report describes liver, kidney and nervous-system toxicity in an Iranian man, described as young and healthy, who had been drinking “herbal water” made from the plant for 2 days to prevent kidney stones — not a supplement capsule. He arrived with a seizure and very high liver enzymes (aminotransferases) and creatinine; after he stopped the remedy his symptoms improved and his liver enzymes returned to normal. It is a single case report — the weakest tier of clinical evidence for causation, and it must be labelled as such — but it is a published, peer-reviewed case in a previously healthy person, and it is the reason "natural means harmless" cannot be asserted about this plant. Evidence tier: case report. Additional reports of acute kidney injury, in some instances accompanied by raised bilirubin, have appeared in the nephrology literature.
Liver injury
Scattered reports associate tribulus-containing preparations with hepatotoxicity, in some cases with a mixed hepatorenal picture. Herbal and dietary supplements as a category are a well-recognised cause of drug-induced liver injury — the U.S. National Institutes of Health (NIH) LiverTox database exists substantially because of it — and multi-ingredient bodybuilding and "test booster" products are among the more frequently implicated groups in that literature. Evidence tier: case reports and case series.
A 2024 case report describes a 46-year-old man who took tribulus supplements daily for 2 months and developed severe jaundice that led to hospital admission. His total bilirubin peaked at 48 mg/dL, with kidney dysfunction at the same time (creatinine 7.1), and his liver biopsy showed features consistent with drug-induced liver injury. After three sessions of plasmapheresis (blood-plasma exchange) his bilirubin fell, his kidneys recovered, and at follow-up his bilirubin was 1.1 mg/dL. Evidence tier: case report.
Three caveats that cut in both directions, stated so the reader can weigh them:
- Case reports cannot establish causation. Temporal association is not proof, and confounders abound.
- Multi-ingredient products muddy attribution. Many implicated products contained several botanicals, and some may have contained undeclared substances — which is itself an argument against the category rather than a defence of it. A product that injured someone because it was contaminated is still a product bought as tribulus.
- Case reports are under-reported, not over-reported. Most supplement-associated adverse events never reach the literature: no clinician suspects the supplement, no analysis of the product is performed, no report is written. The published cases are a floor, not a ceiling.
On the other side of the record, a meta-analysis of eight randomized trials in men with erectile dysfunction (published online in 2025) found no difference in the incidence of adverse events between tribulus and placebo; erectile-function scores (IIEF-5) were higher than with placebo (mean difference 3.23), and total testosterone did not differ between the groups.
The warning signs of liver and kidney injury are dark urine, markedly reduced urine output, ankle swelling, yellowing of the eyes or skin, persistent nausea, pain in the right upper abdomen, or unusual fatigue; hospitals treat these as signs of possible liver or kidney injury that need prompt testing. Relevant background: Kidney Disease, Liver Disease, and the liver function tests used to assess it.
Gynecomastia and Priapism
Gynecomastia — breast tissue development in men — has been reported in association with tribulus-containing products, including in the surgical and breast literature. It is worth pausing on how ironic that is: a product sold to enhance masculinity, associated with the one visible sign men most associate with the opposite. Evidence tier: case report. See Gynecomastia for the condition itself.
The mechanism question here is genuinely interesting and points somewhere uncomfortable. Gynecomastia typically reflects a shift in the effective oestrogen-to-androgen balance in breast tissue. Tribulus does not raise testosterone, so a straightforward androgenic explanation is unavailable. Two possibilities remain, and they are not mutually exclusive:
- An unrecognised effect of plant constituents on steroid receptors or steroid metabolism — plausible, given that steroidal saponins are steroid-skeleton molecules, and entirely unproven in humans.
- Undeclared contents. An aromatisable anabolic steroid is a classic cause of gynecomastia. Given the documented contamination of this product category (see below), some reported cases may reflect what was added rather than the plant. This does not reduce the practical risk to a buyer by one bit — the bottle said tribulus.
Priapism — a prolonged, painful erection unrelated to sexual arousal — has also been reported in the urology literature in association with tribulus use. This is worth knowing because priapism is a urological emergency: sustained beyond a few hours it can cause permanent tissue damage and lasting erectile dysfunction. Hospitals treat an erection lasting more than four hours as an emergency. In the published tribulus case, a 36-year-old man's priapism lasted 72 hours and needed a surgical shunt to resolve, with lasting negative effects on his sexual function. Evidence tier: case report.
Adulteration and Doping Positives
For many users this is the largest real-world risk attached to tribulus, and it is not a risk from the plant.
Products sold as tribulus or as tribulus-containing "test boosters" have been found to contain undeclared anabolic-androgenic steroids or related banned substances, and athletes have returned positive doping tests as a result. The landmark quantification is Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids — results of an international study (International Journal of Sports Medicine, 2004), which examined 634 supplements making no hormonal claims, bought in 13 countries, and found that 94 of them (14.8%) contained anabolic steroids not declared on the label — 21.1% of products from companies that also sold prohormones and 9.6% from companies that did not. The survey covered supplements in general, not tribulus specifically. Subsequent work on supplements cross-contaminated and faked with doping substances has continued to document the problem.
Two routes, identical consequences:
- Cross-contamination in facilities that handle both hormonal and botanical products without adequate segregation and cleaning. Trace quantities are pharmacologically meaningless and analytically decisive: anti-doping laboratories detect far below any active dose. You get the sanction without the effect.
- Deliberate spiking, which is fraud and commercially rational fraud — the product "works," customers repurchase, the label stays legal-looking. This is the most parsimonious explanation for some dramatic personal testimonials in this category, and possibly for some of the gynecomastia reports.
The perverse implication bears repeating from the performance page: a strong subjective effect from a tribulus product is a reason for concern rather than reassurance. The herb repeatedly failed to do anything measurable in controlled trials, so a dramatic effect raises the probability that the bottle contains something the label does not mention.
Mitigation is third-party batch certification for banned substances — see USADA Supplement 411. Understand exactly what it buys: batch verification of identity and absence of prohibited substances. Not efficacy. A certified tribulus product is a clean product with no demonstrated ergogenic effect.
Ruminant Tribulosis: The Veterinary Context
This section is here for a specific reason, and the reason is not scaremongering. It is included because it is the clearest available demonstration that this plant is biologically potent — and because it must be labelled correctly so nobody mistakes it for a human supplement risk.
Tribulosis is a recognised veterinary syndrome in sheep, and to a lesser extent other ruminants, grazing Tribulus terrestris heavily — classically on drought-affected rangeland where the plant is one of the few green things available. It has been documented in the Australian and South African veterinary literature, where the presentation resembles the condition known as geeldikkop. The core problem is hepatogenous photosensitisation:
- Steroidal saponins ingested in quantity are metabolised in the rumen to compounds that damage the liver and, in particular, obstruct the small bile ducts — often with crystalline deposits visible on histology.
- The damaged biliary system fails to clear phylloerythrin, a photodynamic breakdown product of chlorophyll normally excreted in bile.
- Phylloerythrin accumulates in the circulation and reaches the skin, where sunlight activates it — producing severe inflammation, swelling and necrosis of unpigmented, unwooled skin: face, ears, muzzle. Hence the traditional name "yellow big head."
- Affected animals show jaundice, weight loss and severe photosensitivity, and mortality can be significant in an outbreak.
A separate syndrome, sometimes called tribulus "staggers," has been described in sheep in Australia grazing the plant over prolonged periods, involving progressive hind-limb weakness and incoordination attributed to a neurological lesion. It is distinct from the photosensitisation syndrome.
What this is not: it is not a prediction about human supplement use, and this page is not claiming that a capsule of standardized extract will cause liver failure. The differences are fundamental — ruminant digestion with rumen microbial metabolism that humans do not possess, intakes measured in kilograms of whole plant daily over weeks, and animals under drought and nutritional stress. Those distinctions are real and they matter.
What it is: proof that the saponins in this plant, at sufficient exposure and in a susceptible physiology, are hepatotoxic. That is a fact about the chemistry, and it makes the human case reports of hepatobiliary and renal injury considerably less surprising than they would otherwise be. The two bodies of evidence point at the same organ systems by the same broad class of compound. Any page that mentions the plant's biological activity while omitting the one syndrome where its toxicity is fully characterised has left out the informative part.
Rat work points at a specific compound. In a 2022 study, terrestrosin D, a major spirostanol saponin isolated from tribulus fruit, was given by mouth to rats at 5–15 mg/kg daily for 28 days and caused liver and kidney toxicity; it accumulated in the liver and kidneys, and the toxicity reversed 14 days after dosing stopped. This is an animal result, not a human one, but it links one named tribulus saponin to the same organs as the human case reports.
Interactions and Who the Research Raises Concerns For
Groups with the clearest concerns:
- Pregnancy, attempting to conceive, and breastfeeding. Animal data raise reproductive-toxicity and uterine-stimulant concerns, and there is no adequate human safety evidence. This is the clearest concern on the list.
- Children and adolescents. No safety data exist, and the product is marketed on hormonal claims while their hormone systems are still developing.
- Existing significant liver or kidney disease, given the documented case reports and the veterinary hepatotoxicity data. See Liver Disease and Kidney Disease.
- Anyone subject to drug testing in sport or employment, because of the contamination record.
Possible interactions and conditions with unclear safety:
- Hormone-sensitive conditions — including some breast and prostate concerns. Activity at steroid receptors has been reported in animal models, the human picture is unclear, and unclear is not the same as safe. See Prostate Conditions.
- Diabetes medication. Preliminary data suggest possible glucose-lowering activity, which could stack with medication and increase hypoglycaemia risk.
- Blood-pressure medication and diuretics. Consistent with the plant's traditional diuretic use, additive effects are plausible.
- Lithium. Diuretic-type herbs can alter lithium clearance, and lithium has a narrow therapeutic window.
- Any anticoagulant, or before surgery. A general precaution for botanicals with incompletely characterised pharmacology.
- Statins and other drugs cleared by CYP3A4. A 2024 case report describes a 71-year-old man who developed rhabdomyolysis (muscle breakdown) with a mild rise in liver enzymes after taking tribulus while on long-term atorvastatin. The authors cite recent research suggesting tribulus is a moderate inhibitor of CYP3A4, an enzyme that plays a significant role in breaking down statins and many other commonly prescribed medicines. Evidence tier: case report.
- A history of priapism, sickle cell disease, or use of medication for erectile dysfunction. Given the published priapism report, this combination carries an added concern.
- Kidney stones. Despite the traditional urinary use, there is no rigorous human evidence that tribulus prevents or dissolves stones, and no evidence it is safe in active stone disease. The 2010 case of liver, kidney and nervous-system toxicity above occurred in a man drinking the plant's herbal water to prevent kidney stones. See Kidney Stones.
What the Research Says About Product Quality
The points below gather what the sections above report about tribulus products and their risks, as information rather than as a buying guide.
- What the trials support. Testosterone and muscle claims are NOT SUPPORTED by controlled trials. Desire has randomized evidence, modest and mixed.
- Single-ingredient products. Blends, proprietary formulas and pre-workouts do not show how much tribulus they contain.
- Plant part stated on the label. Plant part is the largest single source of variation; a label without it leaves that variable undisclosed.
- A named marker compound with a percentage — a protodioscin figure is more informative than total saponins alone.
- Independent third-party testing, and batch certification for banned substances, are the checks on the contamination record described above — the record that matters to anyone subject to drug testing.
- Explicit anabolic or testosterone claims. Those claims are refuted, and the products carrying them are over-represented in contamination findings.
- The bottle and the batch number. If something goes wrong, the batch is the only way anyone can determine what was actually in it.
- Doses studied. Trials used roughly 250 to 1,500 mg of extract per day, commonly taken with food to reduce stomach upset.
- Duration. Trials ran from a few weeks to about twelve weeks; longer-term safety is unstudied. In the meta-analysis above, total testosterone did not differ from placebo, so a testosterone test does not track any effect of tribulus.
- Medication lists. Supplements are the class of product patients most often leave off a medication list, which hides the interactions listed above from clinicians and pharmacists.
- Warning signs reported with the harms above: dark urine, reduced urine output, yellowing of the eyes or skin, right-upper-abdominal pain, breast swelling or tenderness, or an erection lasting more than four hours. Hospitals treat jaundice, failing urine output and an erection lasting more than four hours as urgent.
Key Research Papers
Papers are cited by their PubMed identifier (PMID); the topic searches gather the wider literature on each subject.
- Ganzera M, Bedir E, Khan IA (2001). Determination of steroidal saponins in Tribulus terrestris by reversed-phase high-performance liquid chromatography and evaporative light scattering detection. J Pharm Sci 90(11):1752-8. The chromatographic method work underlying the variability finding — PubMed PMID: 11745732
- Dinchev D, Janda B, Evstatieva L, Oleszek W, Aslani MR, Kostova I (2008). Distribution of steroidal saponins in Tribulus terrestris from different geographical regions. Phytochemistry 69(1):176-86. The direct evidence that regional material differs in saponin profile, the paper behind this page's sourcing section — PubMed PMID: 17719068
- Chhatre S, Nesari T, Somani G, Kanchan D, Sathaye S (2014). Phytopharmacological overview of Tribulus terrestris. Pharmacogn Rev 8(15):45-51. Broad survey of constituents and reported activities — PubMed PMID: 24600195
- Topic search — saponins in Tribulus terrestris, chemistry and bioactivity, including the Phytochemistry Reviews treatment from 2005 and later reviews of the plant's phytochemistry, pharmacology and toxicology: PubMed search
- Topic search — protodioscin quantification, standardization and stability, including furostanol-to-spirostanol conversion during processing: PubMed search
- Talasaz AH, Abbasi MR, Abkhiz S, Dashti-Khavidaki S (2010). Tribulus terrestris-induced severe nephrotoxicity in a young healthy male. Nephrol Dial Transplant 25(11):3792-3. The case of liver, kidney and nervous-system toxicity after drinking the plant's herbal water to prevent kidney stones — PubMed PMID: 20667992
- Ryan M, Lazar I, Nadasdy GM, Nadasdy T, Satoskar AA (2015). Acute kidney injury and hyperbilirubinemia in a young male after ingestion of Tribulus terrestris. Clin Nephrol 83(3):177-83. The further renal case literature — PubMed PMID: 25295577
- Topic search — hepatotoxicity and drug-induced liver injury associated with tribulus and with bodybuilding supplements: PubMed search
- Jameel JK, Kneeshaw PJ, Rao VS, Drew PJ (2004). Gynaecomastia and the plant product “Tribulis terrestris”. Breast 13(5):428-30. The breast-surgical case report of gynecomastia in a young weight-trainer — PubMed PMID: 15454201
- Campanelli M, De Thomasis R, Tenaglia RL (2016). Priapism caused by ‘Tribulus terrestris’. Int J Impot Res 28(1):39-40. The priapism case report, a urological emergency — PubMed PMID: 26631925
- Geyer H, Parr MK, Mareck U, Reinhart U, Schrader Y, Schänzer W (2004). Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids – results of an international study. Int J Sports Med 25(2):124-9. The contamination survey of products making no hormonal claims — PubMed PMID: 14986195
- Topic search — nutritional supplements cross-contaminated and faked with doping substances: PubMed search
- Topic search — hepatogenous photosensitisation and geeldikkop in sheep grazing Tribulus terrestris, the veterinary tribulosis literature: PubMed search
- Topic search — tribulus staggers, the separate neurological syndrome described in sheep grazing the plant: PubMed search
- Topic search — the plant's reported hypoglycaemic activity, relevant as a possible additive effect with diabetes medication rather than as a treatment: PubMed search
- Mohy-Ud-Din N, Jonassaint N (2024). Severe Liver and Renal Injury From Tribulus Terrestris. ACG Case Rep J 11(2):e01267 — PubMed PMID: 38328764
- Huff R, Karpinska-Leydier K, Maddineni G, Begosh-Mayne D (2024). Rhabdomyolysis Risk: The Dangers of Tribulus Terrestris, an Over-the-Counter Supplement. Am J Case Rep 25:e943492 — PubMed PMID: 39012853
- Sun XC, Song X, Guo F, Yuan YH, Wang SY, Wang S, Liu KL, Lv XY, Han B, Zhang C, Liu JT (2022). Terrestrosin D, a spirostanol saponin from Tribulus terrestris L. with potential hepatorenal toxicity. J Ethnopharmacol 283:114716 — PubMed PMID: 34626781
- Suharyani S, Amanda B, Angellee J, William W, Hariyanto TI, I'tishom R (2026). Tribulus terrestris for management of patients with erectile dysfunction: a systematic review and meta-analysis of randomized trials. Int J Impot Res 38(1):11-18 — PubMed PMID: 40360723
Connections
- All Herbs
- Tribulus terrestris (main article)
- Tribulus — Benefits Deep Dive
- Tribulus and Testosterone: The Claim Examined
- Tribulus for Libido and Sexual Function
- Tribulus for Athletic Performance
- Liver Disease
- Kidney Disease
- Kidney Stones
- Prostate Conditions
- Benign Prostatic Hyperplasia
- Gynecomastia
- Liver Function Tests
- Testosterone Test
- All Lab Tests
- Milk Thistle
- Saw Palmetto
- Ashwagandha
- Maca
- Toxins
Safety and disclaimer. This page is health information, not medical advice. Tribulus is not a benign product: published case reports link it to severe kidney injury and to liver injury, gynecomastia has been reported in men, and a priapism case has been published — hospitals treat an erection lasting more than four hours as an emergency. The research raises the clearest concerns for pregnancy, attempts to conceive, breastfeeding, children and adolescents, and significant liver or kidney disease; possible interactions are described above for hormone-sensitive conditions, diabetes medication, blood-pressure medication, diuretics, lithium, anticoagulants, statins and planned surgery. For anyone drug-tested in sport or at work, this product category carries a documented record of contamination with undeclared anabolic steroids. Dark urine, reduced urine output, ankle swelling, yellowing of the eyes or skin, persistent nausea, right-upper-abdominal pain, or breast swelling or tenderness are the warning signs reported with these harms.